Kronos Bio (KRON) said Thursday it agreed to be acquired by Concentra Biosciences for $0.57 in cash per share, plus a non-tradeable contingent value right.
The CVR entitles holders to potential future payments based on the proceeds from certain asset dispositions and realized cost savings, subject to specific terms laid out in the agreement.
A Concentra subsidiary is expected to commence a tender offer by May 15.
The transaction is anticipated to close by mid-2025, Kronos Bio said.
Shares of Kronos were down nearly 23% in recent trading.
Price: 0.69, Change: -0.20, Percent Change: -22.64
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。